Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A subtype of large cell neuroendocrine lung carcinoma characterized by the presence of large neuroendocrine cells in combination with adenocarcinoma, squamous cell carcinoma, giant cell carcinoma and/ or spindle cell carcinoma.
Biomarker and diagnostic research for lung combined large cell neuroendocrine carcinoma has been reported in the published literature.
No clinical trials have been registered for lung combined large cell neuroendocrine carcinoma.
63 publications have been identified in PubMed for lung combined large cell neuroendocrine carcinoma. Research spans Case Report / Case Series (35%), Basic Science / Preclinical (22%), and Clinical Trial Publication (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 22 | 35% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 5:31 PM UTC
Laboratory research |
14 |
22% |
Clinical study results | 12 | 19% |
Research summaries | 6 | 10% |
Disease patterns and progression | 6 | 10% |
Testing and diagnosis research | 2 | 3% |
Other research | 1 | 2% |
Walter TP (2026). [PMID: 41774886](https://pubmed.ncbi.nlm.nih.gov/41774886/). *J Clin Oncol*. [Clinical Trial Publication]
Wang Z (2026). [PMID: 41684943](https://pubmed.ncbi.nlm.nih.gov/41684943/). *bioRxiv : the preprint server for biology*. [Case Report / Case Series]
Gujarathi R (2026). [PMID: 41968866](https://pubmed.ncbi.nlm.nih.gov/41968866/). *Cancer Med*. [Epidemiology / Natural History]
Zhao Y (2026). [PMID: 42231825](https://pubmed.ncbi.nlm.nih.gov/42231825/). *Cancer Rep (Hoboken)*. [Clinical Trial Publication]
Yücel H (2026). [PMID: 41598557](https://pubmed.ncbi.nlm.nih.gov/41598557/). *Journal of clinical medicine*. [Clinical Trial Publication]
Yang L (2026). [PMID: 42218257](https://pubmed.ncbi.nlm.nih.gov/42218257/). *NPJ Digit Med*. [Diagnostic / Biomarker]
Hung YP (2026). [PMID: 41293870](https://pubmed.ncbi.nlm.nih.gov/41293870/). *Histopathology*. [Basic Science / Preclinical]
Tsuji K (2026). [PMID: 42059931](https://pubmed.ncbi.nlm.nih.gov/42059931/). *Virchows Arch*. [Case Report / Case Series]
Kenmotsu H (2026). [PMID: 42000139](https://pubmed.ncbi.nlm.nih.gov/42000139/). *Lung Cancer*. [Clinical Trial Publication]
Tsuchiya M (2026). [PMID: 41499092](https://pubmed.ncbi.nlm.nih.gov/41499092/). *Pathology international*. [Case Report / Case Series]
AI-curated news mentioning lung combined large cell neuroendocrine carcinoma
Updated Jul 29, 2026
The FIRST-NEC GFPC 01-2022 trial protocol outlines an externally controlled trial to evaluate first-line immunochemotherapy for advanced large cell neuroendocrine lung carcinomas. This study aims to enhance treatment strategies for this rare cancer type.